We present a case of recovery from fulminant hepatic failure secondary to high serum levels of fluconazole precipitated by amphotericin B induced renal dysfunction. Fluconazole dose adjustment or alternative antifungal treatment should be considered in patients with impaired renal function.
Fluconazole is commonly used for the treatment of severe fungal infections. Its oral formulation makes it particularly suitable for prolonged therapy. Toxicity related to the drug is rare and there have been few reports of severe hepatitis all with a fatal outcome [1] [2] [3] . We report survival of a patient following intensive care support of fulminant liver failure from fluconazole toxicity.
CASE HISTORY
A 45-year-old Aboriginal female was referred to hospital because of a mass in her left inguinal region. Chest X-ray showed a cavitating lesion in the right lung. Her past medical history included noninsulin-dependent diabetes mellitus, hypertension, COAD, positive syphilis serology, excessive alcohol intake, smoking and analgesic abuse. Cryptococcus neoformans was grown from sputum and cerebrospinal fluid (CSF). A fine needle aspiration from the inguinal mass was typical of a lymph node and cultures and special stains were negative. Liver and renal functions were normal. She was treated with amphotericin B 40 mg intravenously daily for two weeks and discharged on oral fluconazole 400 mg daily. A repeat CSF after 21 days of treatment showed the white cell count improved from 18x10 6 /l to 1x10 6 /l and no cryptococcus was identified on cytology or culture. Liver and renal functions remained normal. Due to poor compliance, only five weeks of oral fluconazole 400 mg daily was completed. The patient presented again four weeks after she stopped taking oral fluconazole with shortness of breath, cough, fever and headaches. The CSF showed a mononuclear leucocytosis of 1x10 6 /l, with a protein of 840 mg/l and glucose of 2.4 mmol/l. No organisms were seen on CSF microscopy and cultures showed no growth. The CSF cryptococcal antigen (Latex) test was positive. Titration was not performed. The blood antigen titre was 1:64. Because of concerns regarding patient compliance, intravenous amphotericin B 40 mg daily and oral fluconazole 400 mg daily were recommenced. After two weeks of this treatment, the cryptococcal blood titres were 1:256. The CSF showed no organisms on gram or India ink staining and sterile culture. There was a persisting CSF mononucleosis of 1x10 6 /l and CSF cryptococcal antigen remained positive with a titre of 1:2. Intravenous amphotericin B was continued, although the dose was reduced to 35 mg daily in view of deteriorating renal function. The serum creatinine rose from 0.08 to 0.11 mmol/l. The dose of fluconazole was not altered as the liver function and transaminases remained normal.
The patient complained of persisting headaches and there were difficulties in controlling her hypertension. Antihypertensive therapy consisted of lisinopril 10 mg daily, atenolol 25 mg daily and additional amlodipine was used for acute rises in blood pressure. She also had episodes of collapse associated with hypoglycaemia responding to intravenous boluses of 50% dextrose. On day 25 of intravenous amphotericin, the aspartate transaminase (AST) was 3202 U/l, alanine transaminase (ALT) 1281 U/l and prothrombin time (PT) 21 seconds. The patient had not received any paracetamol and the serum paracetamol level was below 10 mmol/l. In view of the acute onset of hepatic failure of unknown aetiology the patient was transferred to intensive care at a tertiary referral hospital. On admission she was drowsy and disorientated with no localizing neurological signs. She was not jaundiced. The liver span was 15 cm and tender. The spleen was not palpable. The abdomen was distended with shifting dullness. Two hours after admission she had a grand mal seizure complicated by aspiration of vomitus. She was intubated and ventilated. Noradrenaline to 20 µg/min was required to support the circulation. Further 50% dextrose boluses and a 20% dextrose infusion were required to maintain a blood glucose greater than 5 mmol/l. She was started empirically on cefotaxime 1g eight hourly. In view of impaired renal function, amphotericin B was changed to liposomal amphotericin 70 mg daily for ongoing treatment of cryptococcal disease. She was anuric for the first eight hours after admission. Renal support included mannitol boluses and frusemide by infusion.
Severe acute hepatic failure was evidenced by marked elevation of hepatocellular enzymes, prolonged prothrombin time, hypoglycaemia and hyperammonaemia (Table 1) . Anti Hepatitis A IgM and Hepatitis B surface antigen, cytomegalovirus, herpes simplex virus 1 and 2 and HIV were negative. Hepatitis C RNA was not detected by PCR. Abdominal ultrasound confirmed the liver span of 15 cm with no focal lesions. There was no evidence of biliary tract pathology. The inferior vena cava and hepatic veins were patent with normal flow on Doppler, as were the portal vein and hepatic artery. There was a moderate amount of ascites. The kidneys were of normal size, with normal depth of parenchyma and without pelvic dilatation or calculi. The serum level of fluconazole, taken four days after the drug was ceased, was 40 mg/l. The therapeutic level of fluconazole has not been established. When treating deep mycoses with 400 mg/day, laboratory reference values for plasma trough concentrations may be expected to reach 12 mg/l 3, 4 . A liver biopsy was not performed due to coagulopathy, cardiovascular instability and poor gas exchange. The peak PT was 58 seconds on day 27.
In view of concerns regarding compliance with medication, alcohol consumption, diabetes and intercurrent cryptococcal infection, liver transplantation was unlikely to be available as salvage therapy. Full supportive medical therapy was pursued. With supportive care her renal and hepatic function improved over three weeks and she was discharged from ICU. Discharge home to independent living was made two days after she left ICU.
DISCUSSION
Fluconazole is a bis-triazole fungistatic drug which acts by inhibiting membrane sterol synthesis and preventing fungal cell replication 5 . Pharmacokinetic properties of fluconazole include nearly complete bioavailability, low plasma protein binding, wide distribution to body tissues and fluids including CSF, and excretion primarily by kidneys 5 therapeutic activity and is used for prevention and treatment of a broad range of fungal infections 6 . Amphotericin B initial therapy and fluconazole maintenance is the treatment of choice for cryptococcal meningitis 7 . A recommended regimen consists of a three-week course of amphotericin B followed by fluconazole for 10 to 12 weeks after cultures of CSF become negative 8 .
Fluconazole is much more selective for fungal cytochrome P-450 isoenzymes than mammalian cells 5 . Most evidence argues against a detrimental effect of fluconazole on mammalian steroid hormone production 5 . Fluconazole-induced liver toxicity is rare. Severe hepatitis associated with fluconazole has been reported in HIV patients 1, 2 . These patients were receiving other hepatotoxic drugs 1 or had already compromised liver function 2 . Our case presents hepatic failure in a young HIV-negative female who had previously normal liver function and who was not receiving any other hepatotoxic agents. Although her alcohol consumption had been hazardous in the past, there was no clinical or biochemical evidence of alcoholic hepatitis or cirrhosis. Hepatic function had been normal until the episode of collapse with hypoglycaemia on the second admission. Whilst her antihypertensive medications have been rarely associated with severe liver injury, the clinical picture combined with high serum fluconazole levels makes fluconazole more likely to be the cause of her liver injury. Impaired renal excretion of fluconazole was precipitated by concurrent amphotericin B administration. Toxicity is thought to be dose-dependent 3 .
A previous case of fluconazole hepatoxicity with fatal outcome has been reported in the setting of renal failure 3 . In that case the serum level of fluconazole was 982 mg/l (expected trough range, 6 to 15 mg/l) in the patient with a creatinine of 0.23 mmol/l. Our patient had severe liver failure with much lower serum fluconazole levels. The mechanism underlying accumulation of fluconazole in the case described in the literature and in our patient appeared to have been failure of excretion of unmetabolized drug due to renal impairment 3 .
We conclude that fluconazole-induced fulminant liver failure can recover with conservative management. This differs from other reports where liver failure was fatal [1] [2] [3] . We suggest that fluconazole should be administered with caution and dose adjusted in the patients with renal impairment. There are no commercially available kits for the measurement of fluconazole levels in plasma. Gas-liquid chromatography methods exist but need to be standardized in individual laboratories 9 . The cost of administration and convenience of oral therapy places fluconazole favourably for the management of cryptococcal meningitis. Regimens for adjusting fluconazole dose based on creatinine clearance have been suggested 10 . With creatinine clearance of more than 50 ml/min, the full dose of fluconazole can be given. Creatinine clearance between 20 and 50 ml/min requires a 50% reduction in dose. With creatinine clearance below 20 ml/min, a 75% reduction of the dose should be given. In the absence of a commercial kit, routine measurement of plasma levels is not a practical option but clearly would be useful when fluconazole needs to be used in the setting of changing renal function. Special attention should be paid to renal and liver function during standard amphotericin B and fluconazole treatment. Liver enzymes should be monitored and fluconazole discontinued early when liver enzyme abnormalities develop. The safest option in the presence of renal impairment may be substituting liposomal amphotericin for fluconazole.
